DPP4 and obesity due to melanocortin 4 receptor deficiency: Given the success of incretin-based drugs in treating both diabetes and obesity, and their potential for treating NAFLD, further dissection of the regulation of hepatic metabolic pathways by DPP4 is warranted (27–33).